


NexoBrid[®]

Disruptive Bioactive Therapy
for Burn Care



Eschar Removal

Critical First Step in Burn Care



Prevents infection
and sepsis

Stops deterioration
and scarring

Tissue visible for
medical evaluation

Traumatic SOC

Surgical, Non-Selective



Loss of healthy
tissue and blood

Challenging in
delicate areas

Requires surgical team,
operating room

NexoBrid: Rapid, Effective, and Selective



- Sterile mixture of proteolytic enzymes
- Globally approved for eschar removal in adult and pediatric burn patients in 40+ countries
- 14K+ patients treated to-date
- Topical application at bedside
- Minimizes need for surgery and significantly reduces blood loss
- Improves patient outcomes
- Removes eschar within 4 hours
- Enables visual medical assessment
- Extensive government funding: \$130M+ received from BARDA and DoD
- Commercially available in U.S. by Vericel